LivaNova's AI Edge: Strategy and Stakes at Piper Sandler

NEW YORK, NY – November 25, 2025 – When LivaNova’s Chief Financial Officer, Alex Shvartsburg, takes the stage for a fireside chat at the Piper Sandler Healthcare Conference next month, the investment community will be listening for more than just a standard business update. The presentation comes as the London-based medical technology firm rides a wave of strong financial performance, fueled by innovative products that are increasingly embedding data and machine intelligence into critical care settings. Shvartsburg’s challenge, and opportunity, will be to articulate a clear narrative that connects today's robust sales to a compelling, technology-driven vision for the future.

Riding a Wave of Financial Momentum

LivaNova arrives at the high-profile conference on a significant hot streak. The company recently posted impressive third-quarter 2025 results that surpassed analyst expectations, prompting management to raise its full-year guidance for revenue, earnings, and cash flow. Total revenue climbed to $357.8 million, a 12.5% organic increase year-over-year, handily beating forecasts. This performance translated directly to the bottom line, with adjusted earnings per share of $1.11, well ahead of the consensus estimate of $0.92.

This financial strength is not a monolith; it’s a story of two powerful business segments performing in concert. The Cardiopulmonary division, which provides essential equipment for open-heart surgeries, saw its revenue jump by an impressive 18%. Simultaneously, the Neuromodulation segment, known for its therapies for drug-resistant epilepsy, grew by a solid 6.9%. This balanced growth has instilled confidence among investors and analysts, who currently hold a consensus "Strong Buy" rating on the stock, with some setting price targets that suggest continued upside.

For Shvartsburg, a finance veteran with a reputation for disciplined execution, these numbers provide a powerful foundation. His task at Piper Sandler will be to move beyond the figures and explain the strategic drivers behind them, reassuring the market that this momentum is sustainable and not just a temporary surge.

The Engine Room: AI and Innovation in Practice

At the core of LivaNova’s recent success, particularly in its Cardiopulmonary business, is the Essenz Perfusion System. This is not your standard heart-lung machine. It represents a significant leap forward by integrating next-generation hardware with a sophisticated software layer of real-time monitoring and machine intelligence. During complex cardiopulmonary bypass procedures, the system provides clinicians with data-driven insights, helping to optimize patient management and potentially improve outcomes. This is a prime example of AI at work, moving from a theoretical concept to a practical tool in the operating room.

The business impact is already clear. The Essenz system has been a primary engine of the Cardiopulmonary segment's double-digit growth. Its recent launch in China, the world's second-largest market for such devices, has opened a massive new channel for expansion. This strategic move demonstrates LivaNova's ability to not only innovate but also execute on a global commercial scale.

This focus on intelligent devices aligns perfectly with the broader transformation sweeping the MedTech industry. As care delivery shifts toward more connected, data-centric models, companies that can successfully embed AI and analytics into their products are poised to lead. LivaNova’s Essenz system is a tangible proof point that the company is not just participating in this trend but is actively shaping it, creating a defensible competitive advantage built on more than just hardware.

Charting the Future: From Epilepsy to Sleep Apnea

While the Cardiopulmonary business delivers impressive current results, investors will be keenly interested in LivaNova’s next act. Much of that future potential lies within its Neuromodulation pipeline, specifically with the aura6000 System for treating Obstructive Sleep Apnea (OSA). This implantable device represents a significant market opportunity, targeting a widespread condition with a novel therapeutic approach.

The company has been making steady progress on this front. The pivotal OSPREY clinical trial is nearing a crucial milestone, with all patients expected to complete the primary endpoint follow-up this month. Based on promising early data, LivaNova anticipates submitting its application for regulatory approval to the FDA in the first half of 2025. Shvartsburg will likely be pressed for details on the commercialization strategy and the timeline to profitability for this new venture, which the company projects could reach break-even by 2029.

This forward-looking investment in the aura6000 system, alongside the company's established VNS Therapy for epilepsy and efforts to expand its use in treatment-resistant depression, showcases a balanced strategy. LivaNova is leveraging its profitable, mature businesses to fund the development of its next generation of growth drivers. Communicating this long-term value creation story will be a critical part of the CFO's mission at the conference.

The CFO's Strategic Narrative in a Competitive Arena

In the hyper-competitive MedTech landscape, where giants like Medtronic, Abbott, and Boston Scientific dominate, a clear strategic narrative is indispensable. Alex Shvartsburg’s role at the Piper Sandler conference transcends that of a typical financial officer. He must act as a key storyteller, weaving together the threads of strong quarterly earnings, innovative product technology, and a promising R&D pipeline into a cohesive and convincing vision.

His background, with extensive experience in finance leadership and strategic allocation at firms like Thermo Fisher Scientific and Johnson & Johnson, makes him well-suited for this task. He will need to articulate how LivaNova's disciplined financial management enables its ambitious innovation agenda. Investors will want to understand how the company plans to defend its market share with products like Essenz while simultaneously funding the significant costs associated with bringing a new device like aura6000 to market.

The fireside chat format provides the perfect venue for this nuanced discussion. It allows for a deeper dive into strategy than a scripted presentation, giving Shvartsburg the opportunity to address analyst concerns directly and build confidence in the leadership team’s ability to execute. His performance will be measured not just by the financial data he presents, but by his ability to convince the audience that LivaNova has a durable strategy to thrive and innovate in a rapidly evolving industry. The market will be watching closely to see how this story of current success and future ambition resonates with the financial community.